https://corporate.abcam.com/wp-content/uploads/2024/07/SilverAward_2024.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2024-07-16 09:00:382024-07-16 09:00:38Abcam recognized by Stonewall for commitment to LGBTQ+ inclusivity
https://corporate.abcam.com/wp-content/uploads/2024/03/CIteab_2024.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2024-03-25 16:33:532024-03-25 16:33:53Abcam most cited antibody supplier for IHC in 2023
https://corporate.abcam.com/wp-content/uploads/2024/03/Markus-Lusser-panel.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2024-03-18 13:34:372024-03-18 13:35:55Abcam appoints Markus Lusser as new President
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-12-04 21:04:122023-12-04 21:04:12Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-11-17 12:01:532023-11-17 12:01:53Abcam Acquisition by Danaher has Received all Identified Clearances; Transaction Expected to Close on December 6, 2023
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-11-06 21:03:112023-11-06 21:03:11Shareholders of Abcam Approve Proposed Acquisition by Danaher
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-10-23 12:35:242023-10-23 12:37:59Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-10-17 12:33:232023-10-17 12:33:23Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-10-12 12:31:532023-10-12 12:31:53Independent Directors of Abcam highlight compelling reasons for shareholders to support proposed sale to Danaher
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-10-05 13:02:492023-10-05 13:02:49Abcam files and mails Scheme Circular seeking approval of acquisition of Abcam by Danaher for $24.00 per share
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-09-14 19:00:292023-09-15 10:12:20Abcam plc Statement on Dr. Jonathan Milner’s Announcement
https://corporate.abcam.com/wp-content/uploads/2022/11/Alliance-logo-nanoString_PN.png
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-09-13 14:00:102023-09-13 14:01:17NanoString Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-08-31 21:18:082023-08-31 21:18:08Interim results for the six-month period ended 30 June 2023
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-08-28 13:00:192023-08-28 13:00:19Danaher to acquire Abcam for $24.00 per Share
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-07-12 14:27:172023-07-12 14:27:17All Resolutions Withdrawn at Abcam’s EGM
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-07-05 21:54:142023-07-05 21:55:43Trading Update
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-06-28 14:34:132023-06-28 14:34:13Abcam Confirms Dr. Jonathan Milner has Withdrawn EGM Requisition Notice and Related Resolutions
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-06-26 21:16:262023-06-26 21:22:05Abcam plc: FY2024 Guidance
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-06-23 13:43:302023-06-23 13:43:30Abcam Announces Review of Strategic Alternatives
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-06-20 12:09:552023-06-20 12:10:48Abcam highlights successful execution of strategic priorities to drive shareholder value
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-06-16 11:00:462023-06-16 12:10:09Abcam plc files and mails Shareholder Circular calling an Extraordinary General Meeting
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-05-30 21:37:412023-05-30 21:37:41Statement on calling an Extraordinary General Meeting
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-05-17 21:10:192023-05-17 21:10:19Statement on potential Extraordinary General Meeting
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-05-17 14:35:292023-05-17 14:35:29Result of Annual General Meeting
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-05-04 21:35:242023-05-04 21:35:24Business Update
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-05-01 18:16:322023-05-04 18:18:53Comments on Investor Engagement
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-04-17 12:03:002023-04-17 12:05:28Upcoming Abcam Investor Events
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-04-13 21:16:142023-04-13 21:18:36Trading Update
https://corporate.abcam.com/wp-content/uploads/2023/04/Alliance-LP-panel.png
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-04-06 15:00:172023-04-11 15:10:46Lunaphore and abcam announce agreement for primary antibody validation for use on COMET™, combining power of trusted antibody provider with superior multiplex capabilities
https://corporate.abcam.com/wp-content/uploads/2023/03/2022_AR_P500.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-03-30 12:08:032023-03-30 12:10:19Publication of 2022 Annual Report and Accounts and Notice of Annual General Meeting
https://corporate.abcam.com/wp-content/uploads/2023/03/CiteAb2023.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2023-03-27 14:46:392023-03-27 14:56:24abcam named ‘Antibody Supplier of the Year’ by CiteAb
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-03-20 11:11:282023-03-20 11:11:28Final results for the year ended 31 December 2022
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-03-10 09:00:042023-03-13 11:38:33Abcam to Report Full Year Results on Monday, March 20, 2023
https://corporate.abcam.com/wp-content/uploads/2023/01/Abcam_Flags-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-01-30 10:15:342023-02-01 10:40:04Trading Update
https://corporate.abcam.com/wp-content/uploads/2023/01/Blue-plaques-thumbnail.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2023-01-25 09:00:242023-02-06 11:43:24Abcam Unveils New Plaques to Honour Team Behind Breast Cancer Gene Discovery
https://corporate.abcam.com/wp-content/uploads/2022/12/Alliance-logo-small-260x185-1.jpg
185
260
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2022-12-13 17:03:242023-01-09 17:18:44WuXiDiagnostics and Abcam expand existing collaboration to advance companion diagnostics for cancer therapies
https://corporate.abcam.com/wp-content/uploads/2021/09/Abcam_Flags-PN.jpg
350
500
Chris Fisher
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Chris Fisher2022-11-11 15:36:212022-11-11 15:38:41Result of General Meeting – Shareholders approve AIM Delisting
https://corporate.abcam.com/wp-content/uploads/2022/11/Alliance-logo-nanoString_PN.png
350
500
Chris Fisher
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Chris Fisher2022-11-09 11:00:052022-11-09 11:00:05NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research
https://corporate.abcam.com/wp-content/uploads/2021/09/Abcam_Flags-PN.jpg
350
500
Chris Fisher
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Chris Fisher2022-10-17 07:03:452022-10-17 07:03:45Proposed Cancellation of Admission of Ordinary Shares to Trading on AIM and Notice of General Meeting
https://corporate.abcam.com/wp-content/uploads/2021/09/Inv-Pres-news-Sept-2021-BN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-09-12 12:04:262022-09-12 12:07:13Interim results for the period ended 30 June 2022
https://corporate.abcam.com/wp-content/uploads/2021/03/Abcam-sign-PN.jpg
350
500
Chris Fisher
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Chris Fisher2022-09-01 21:22:552022-09-02 08:21:23Abcam to participate in the Morgan Stanley 20th Annual Global Healthcare Conference
https://corporate.abcam.com/wp-content/uploads/2022/08/Abcam-glassdoor.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-08-17 11:17:202022-08-17 11:39:25Notice of Results
https://corporate.abcam.com/wp-content/uploads/2021/03/Abcam-sign-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-07-20 16:28:552022-07-20 16:33:37Trading update for the period ending 30 June 2022
https://corporate.abcam.com/wp-content/uploads/2022/06/TThomas_Panel.jpg
350
500
Chris Fisher
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Chris Fisher2022-06-27 07:00:302022-06-27 09:19:00Appointment of Vice President of Investor Relations
https://corporate.abcam.com/wp-content/uploads/2022/04/Singapore-opening-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-04-27 12:41:472022-04-28 12:09:42Abcam opens new APAC hub in Singapore
https://corporate.abcam.com/wp-content/uploads/2022/03/CiteAb22-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-03-24 10:48:422022-03-25 14:43:07Abcam the Most Awarded Company at 2022 Industry Awards
https://corporate.abcam.com/wp-content/uploads/2022/03/FY2021-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-03-14 09:44:502022-03-14 12:12:53Results for the 12- and 18-month periods ended 31 December 2021
https://corporate.abcam.com/wp-content/uploads/2021/01/Flags-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-02-01 09:32:222022-02-01 09:33:43Trading update for the period ended 31 December 2021
https://corporate.abcam.com/wp-content/uploads/2022/01/Alliance-logo-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-02-01 08:55:502022-02-01 09:15:25Abcam collaborates with Twist Bioscience to enhance antibody discovery for diagnostic and research applications
https://corporate.abcam.com/wp-content/uploads/2022/01/Glassdoor-2022-PN.png
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-01-11 16:54:382024-07-25 12:53:08Abcam in Glassdoor’s Top 5 Best Places to Work in the UK for Second Consecutive Year
https://corporate.abcam.com/wp-content/uploads/2021/12/Alliance-logo-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2022-01-04 08:59:232022-01-05 19:29:17Alamar Biosciences partners with Abcam to drive understanding of the human proteome
https://corporate.abcam.com/wp-content/uploads/2021/10/Alliance-logo-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2021-11-02 12:00:152021-11-02 12:00:15Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
https://corporate.abcam.com/wp-content/uploads/2021/08/GE-v-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2021-10-27 07:02:062021-11-09 17:00:21Abcam completes $340m strategic acquisition and expands kit capacity and capability
https://corporate.abcam.com/wp-content/uploads/2021/09/Inv-Pres-news-Sept-2021-BN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2021-09-13 12:29:422021-09-13 12:58:00Interim results for the 6- and 12-month periods ended 30 June 2021
https://corporate.abcam.com/wp-content/uploads/2021/08/GE-v-PN.jpg
350
500
connective
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
connective2021-08-02 07:00:122021-11-09 17:00:25Abcam to acquire BioVision for $340 million
https://corporate.abcam.com/wp-content/uploads/2021/07/Waltham-PN.jpg
350
500
Pierre Peotta
https://corporate.abcam.com/wp-content/uploads/2022/12/Abcam_Logo-Lockup_primary2.svg
Pierre Peotta2021-07-13 11:15:502021-07-13 12:33:49Abcam opens new US facility in Boston, MAEmail: external.comms@abcam.com
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
Abcam Honoured As One Of The UK’s Best Places To Work In 2020; A Glassdoor Employees’ Choice Award Winner
Abcam delivers outstanding performance in new Biocompare antibody market report
Scientists poised to unlock their understanding of autophagy with new antibody-based insights
Abcam agrees to acquire Expedeon’s Proteomics and Immunology business, expanding offerings into the fast-growing conjugation segment
Abcam and BrickBio announce a partnership to incorporate conjugation-ready sites into recombinant antibodies across Abcam’s portfolio
Engineered knockout cell lysates for reproducible proteomic analysis
Abcam Enters Cell Editing Market Through Acquisition of EdiGene’s Knockout Cell Lines and Lysates Portfolio
New tissue clearing kits and reagents for faster, accurate 3D imaging
NanoString and Abcam Enter Commercial Partnership to Provide Expanded Menu of Antibodies for GeoMx Digital Spatial Profiler
Abcam collaborates with Visikol to develop new tools for improved tissue clearing and 3D imaging